3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
94
Neoplasm Metastasis
6
Breast Diseases
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Primary Breast Cancer ER+ve
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Beast Cancer
1
Mammary Neoplasms, Animal
1
Locoregional Recurrence
1
Lethal Congenital Contracture Syndrome 2
1
Hyperglycemia
1
Hormone Receptor Positive Malignant Neoplasm of Breast
1
HER2-positive Breast Cancer
1
Granulosa cell tumor of the ovary
1
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
1
Endometrial Stromal Tumors
1
Endometrial Hyperplasia
1
ER+ Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Ductal
1
Bulbo-Spinal Atrophy, X-Linked
1
Interventions
Fulvestrant
5
Letrozole
3
Capecitabine
3
ribociclib
2
exemestane
2
dalpiciclib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
Anastrozole
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pegfilgrastim
1
palbociclib
1
margetuximab
1
irinotecan sucrosofate
1
fluzoparib
1
abemaciclib
1
Vinorelbine
1
Trastuzumab
1
Tamoxifen
1
Paclitaxel
1
Liposomes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Cancer Metastatic
×
exemestane
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts
NCT03555877
2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2
Completed
56 enrolled